| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | 0.7 | -4.2 |
| EPS (diluted, $ a share) | $-0.37 | $-0.39 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: LTRN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lantern Pharma Inc.: key numbers
- Share price
- $0.3650Close, Nov 17
- Market cap
- $5.8M
- Shares outstanding
- 15.89MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lantern Pharma Inc.
All →Lantern Pharma Nasdaq/NYSE Compliance Notice
Lantern Pharma Inc. received a deficiency notice from Nasdaq on September 25, 2026, for failing to maintain a minimum market value of listed securities (MVLS) of $35 million for 30 consecutive business days. The company has 180 calendar days, or until March 24, 2027, to regain compliance by maintaining an MVLS of at least $35 million for 10 consecutive business days.
- Counterparty
- Nasdaq
- Term
- 180 days
Lantern Pharma Capital Raise of $4M
Lantern Pharma Inc. entered into a securities purchase agreement for a registered direct offering of 1,469,725 common shares and 2,200,000 pre-funded warrants at $1.09 per share. The offering raised approximately $4 million in gross proceeds, with a concurrent private placement of warrants that could provide an additional $4 million if fully exercised. The company intends to use the proceeds for working capital and general corporate purposes.
- Value
- $4M
- Counterparty
- institutional investor
Lantern Pharma Investor Presentation
Lantern Pharma hosted a live webinar and filed a formal presentation deck (Exhibit 99.1) to discuss its Open-Medicine AI multi-agentic platform for drug development. The presentation highlights the company's AI-driven approach to drug discovery and development, specifically focusing on the Open-Medicine AI platform.
Lantern Pharma Investor Presentation
Lantern Pharma is hosting a live webinar and investor presentation to discuss the growth plan, development roadmap, and economics of its wholly owned subsidiary, Open-Medicine AI. The session will include a live demonstration of the multi-agentic AI platform's capabilities and an overview of the subscription and enterprise licensing model.
- Earnings call
- Sep 23, 2026, 12:30 PM ET